was detected. In the four cases with vein stenosis that accounted for the failure to show significant difference underwent angioplasty the fistulas still failed to develop in renal function compared to the control group. Noneadequately. One patient had a complete occlusion of the theless, the degree of proteinuria was significantly less subclavian vein. In two patients the fistulogram did not in the treatment arm. The main finding from this fivereveal any anatomic abnormality. year assessment, however, was that patients who stopped Finally, notwithstanding the theoretical concerns treatment had significantly worse renal function and about developing hand ischemia with an upper arm fiswere more likely (6 of 14) to progress to end-stage renal tula, only one of the 51 consecutive patients in our study disease (ESRD) compared to those who continued treatreceiving such a fistula developed a clinically significant ment (0 of 13). steal syndrome. Thirty-one of the patients receiving an Clearly, this finding may be criticized for selection upper arm fistula were diabetic.
bias, since patients who opted to continue treatment may on treatment while a significant deterioration was seen dipyridamole, and warfarin should not be used. This is in the control group. This study suggests that treatment based on the results from two randomized controlled of patients with IgA nephropathy and renal impairment trials (RCT), our own three-year study [2] , and that of with dipyridamole and low-dose warfarin retards the deWalker et al [3] , as well as our five-year post-trial assessterioration in renal function. ment [4] , concern about the absence of post-treatment Walker et al showed reduction in proteinuria over a biopsy data, and the potential toxicity from cyclophostwo-year period but, unlike our original study using the phamide.
same triple regimen and the subsequent trial without The authors correctly state that we were able to demcyclophosphamide, failed to show any beneficial effect onstrate reduction in proteinuria and stabilization in reon renal function [3] . The reasons for this difference may nal function at the end of the three-year trial. However, be related to the shorter duration of treatment (2 years the apparent loss of benefit on renal function at the fivevs. 3 years) and the use of warfarin at the higher "antiyear post-trial assessment has been misinterpreted and coagulant doses" (keeping thrombotest between 7 and needs to be qualified. Only half the patients in the treat-15%). ment group remained on treatment with dipyridamole Currently there is no therapy that will cure IgA neand low-dose warfarin at five years, which may have phropathy. It is the most common form of glomerulonephritis worldwide, and is especially frequent in the East among the Chinese and Japanese and an important cause of ESRD. 
